Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Operations (2021 - 2025)

ARS Pharmaceuticals' Cash from Operations history spans 5 years, with the latest figure at 43485000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 203.53% year-over-year to 43485000.0; the TTM value through Dec 2025 reached 170866000.0, down 1361.19%, while the annual FY2025 figure was 170866000.0, 1361.19% down from the prior year.
  • Cash from Operations for Q4 2025 was 43485000.0 at ARS Pharmaceuticals, up from 47047000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 42004000.0 in Q4 2024 and bottomed at 47047000.0 in Q3 2025.
  • The 5-year median for Cash from Operations is 13449000.0 (2021), against an average of 13711150.0.
  • The largest annual shift saw Cash from Operations skyrocketed 341.33% in 2024 before it tumbled 507.18% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 27894000.0 in 2021, then tumbled by 173.48% to 20497000.0 in 2022, then increased by 15.09% to 17405000.0 in 2023, then surged by 341.33% to 42004000.0 in 2024, then plummeted by 203.53% to 43485000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Cash from Operations are 43485000.0 (Q4 2025), 47047000.0 (Q3 2025), and 39592000.0 (Q2 2025).